NTRK2 and Cognitive impairment: Remarkably, treatment with a TrkB agonist rescued both the myelination defect and cognitive impairment, with the rescue depending on the expression of BDNF receptor TrkB in OPCs, demonstrating the important role of BDNF–TrkB signaling in activity‐dependent oligodendrogenesis (Geraghty et al. 2019).